255 related articles for article (PubMed ID: 32582721)
1. Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study.
Tang L; Liu H; Deng H; Zhan X; Fang X; Liao H; Liu Y; Fu L; Fu Z; Liu H; Wu S; Xue Y
Front Med (Lausanne); 2020; 7():197. PubMed ID: 32582721
[No Abstract] [Full Text] [Related]
2. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
Mao YJ; Wang H; Huang PF
J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
[TBL] [Abstract][Full Text] [Related]
4. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
[TBL] [Abstract][Full Text] [Related]
5. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
6. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
[TBL] [Abstract][Full Text] [Related]
7. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H
Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702
[TBL] [Abstract][Full Text] [Related]
8. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias.
Bawazeer GA; Alkofide HA; Alsharafi AA; Babakr NO; Altorkistani AM; Kashour TS; Miligkos M; AlFaleh KM; Al-Ansary LA
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013504. PubMed ID: 34674223
[TBL] [Abstract][Full Text] [Related]
9. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
[TBL] [Abstract][Full Text] [Related]
10. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
[TBL] [Abstract][Full Text] [Related]
12. Uninterrupted or Minimally Interrupted Direct Oral Anticoagulant Therapy is a Safe Alternative to Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation: An Updated Meta-Analysis.
Ottóffy M; Mátrai P; Farkas N; Hegyi P; Czopf L; Márta K; Garami A; Balaskó M; Pótóné-Oláh E; Mikó A; Rostás I; Wobbe B; Habon T
J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32987707
[TBL] [Abstract][Full Text] [Related]
13. Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants.
Petzl A; Derndorfer M; Kollias G; Moroka K; Aichinger J; Pürerfellner H; Martinek M
J Interv Card Electrophysiol; 2021 Jan; 60(1):147-154. PubMed ID: 32144677
[TBL] [Abstract][Full Text] [Related]
14. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
[TBL] [Abstract][Full Text] [Related]
15. One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey.
Bejinariu AG; Makimoto H; Wakili R; Mathew S; Kosiuk J; Linz D; Steinfurt J; Dechering DG; Meyer C; Veltmann C; Kelm M; Frommeyer G; Eckardt L; Deneke T; Duncker D; Müller P
Cardiology; 2020; 145(10):676-681. PubMed ID: 32854099
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation.
Zhao Y; Lu Y; Qin Y
Int J Cardiol; 2018 Nov; 270():167-171. PubMed ID: 29903520
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation.
van Vugt SPG; Westra SW; Volleberg RHJA; Hannink G; Nakamura R; de Asmundis C; Chierchia GB; Navarese EP; Brouwer MA
Europace; 2021 Dec; 23(12):1961-1969. PubMed ID: 34333631
[TBL] [Abstract][Full Text] [Related]
18. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
Nogami A; Harada T; Sekiguchi Y; Otani R; Yoshida Y; Yoshida K; Nakano Y; Nuruki N; Nakahara S; Goya M; Origasa H; Kihara Y; Hirao K; Aonuma K;
JAMA Netw Open; 2019 Apr; 2(4):e191994. PubMed ID: 31002317
[TBL] [Abstract][Full Text] [Related]
20. Periprocedural Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation Without Discontinuation of a Vitamin K Antagonist and Direct Oral Anticoagulants.
Kojima T; Fujiu K; Fukuma N; Matsunaga H; Oshima T; Matsuda J; Matsubara T; Shimizu Y; Oguri G; Hasumi E; Morita H; Komuro I
Circ J; 2018 May; 82(6):1552-1557. PubMed ID: 29657252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
